Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks (ZYME) released Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate (ADC), demonstrating substantial clinical efficacy in platinum-resistant ovarian cancer. The compound achieved a 78.6% objective response rate in FRα-positive patients and 47.4% in FRα-negative patients, suggesting potential utility across patient populations regardless of biomarker status—a meaningful therapeutic advantage in precision oncology.

The durability metrics are clinically noteworthy: median progression-free survival reached 7.6 months across ovarian and endometrial cohorts, with median duration of response not yet reached at data cutoff. This profile indicates sustained anti-tumor activity and supports continued escalation into later-stage trials. The completion of dose optimization cohorts with a favorable tolerability profile and broad therapeutic window reduces development risk and suggests the compound may have differentiated positioning versus existing ADC therapies.

ZW191 addresses a significant unmet need in platinum-resistant ovarian cancer, where treatment options remain limited and prognosis poor. The biomarker-agnostic response pattern may expand addressable patient populations and commercial potential, though confirmatory Phase 2 data will be critical for regulatory pathway clarity and competitive positioning against emerging FRα-targeting competitors.

Sector implication: This development supports the Health Care sector's oncology subsegment, particularly the ADC/biologics space. Positive clinical catalysts in mid-stage biotech compounds typically drive equity valuation expansion and may strengthen investor appetite for precision cancer immunotherapy platforms.